What is the most likely cause of thrombocytosis with macrocytic anemia and how should it be evaluated and managed?

Thrombocytosis with Macrocytic Anemia

The combination of thrombocytosis with macrocytic anemia should immediately raise suspicion for myelodysplastic syndrome (MDS), particularly in older adults, and requires urgent bone marrow evaluation with cytogenetics and molecular testing to exclude this potentially life-threatening diagnosis.

Most Likely Causes

The concurrent presentation of elevated platelets with macrocytic anemia is unusual and narrows the differential significantly:

Primary (Clonal) Causes - Highest Priority

• Myelodysplastic Syndrome (MDS): This is the most critical diagnosis to exclude, as MDS can present with macrocytosis and thrombocytosis, particularly in certain subtypes 1, 2, 3. MDS carries significant mortality risk and requires specific management including potential allogeneic stem cell transplantation.
• Chronic Myelomonocytic Leukemia (CMML): The myeloproliferative variant can present with thrombocytosis and macrocytic changes 4.
• Myeloproliferative Neoplasms (MPNs): Essential thrombocythemia or other MPNs can occasionally present with macrocytosis, particularly if there is concurrent B12/folate deficiency 5, 6, 7.

Secondary Causes

• Concurrent conditions: Iron deficiency anemia (which can cause reactive thrombocytosis) combined with B12/folate deficiency (causing macrocytosis) 8.
• Alcoholism with tissue injury/inflammation: Alcohol causes macrocytosis while concurrent tissue damage drives reactive thrombocytosis 9, 10.
• Medications: Hydroxyurea causes macrocytosis and can paradoxically be associated with thrombocytosis in treatment-resistant cases 1, 4.

Immediate Evaluation Algorithm

Step 1: Confirm and Characterize (Within 48-72 hours)

• Repeat CBC with differential to confirm persistent findings 6
• Peripheral blood smear review - critical to identify:
  • Dysplastic features (pseudo-Pelger-Huët cells, hypogranular neutrophils)
  • Macro-ovalocytes and teardrop cells (suggest megaloblastic or MDS) 1, 11
  • Blast cells 2
• Reticulocyte count: Low/normal suggests production defect (MDS, B12/folate deficiency); elevated suggests hemolysis or bleeding 1

Step 2: Initial Laboratory Workup (Same day as Step 1)

Minimum essential tests 11:

• Vitamin B12 and folate levels
• Serum ferritin, transferrin saturation, TIBC
• CRP or ESR (inflammation marker)
• LDH (elevated in MDS and hemolysis)
• Liver function tests
• TSH (hypothyroidism causes macrocytosis)
• Creatinine (renal disease)

If B12 <200 pg/mL or borderline (200-400 pg/mL) 11:

• Methylmalonic acid and homocysteine levels (both elevated in true B12 deficiency) 1, 9

Step 3: Risk Stratification for MDS/MPN

Proceed URGENTLY to bone marrow evaluation if ANY of the following 2, 3:

• Age >60 years with unexplained macrocytosis and thrombocytosis
• MCV >115 fL (highly suspicious for MDS or severe B12 deficiency) 9
• Presence of dysplastic features on smear
• Cytopenias in other cell lines
• Unexplained splenomegaly 1
• Elevated LDH without other explanation
• No clear secondary cause identified

Bone marrow examination must include 2, 3:

• Aspirate and biopsy with morphology
• Cytogenetics (karyotype)
• Molecular testing: JAK2V617F, CALR, MPL mutations for MPNs 6, 7
• Next-generation sequencing panel for MDS-associated mutations 2
• Flow cytometry if available 2

Step 4: If B12/Folate Deficiency Confirmed

Critical caveat: Never treat with folate alone before excluding B12 deficiency, as this can precipitate subacute combined degeneration of the spinal cord 12, 13.

For B12 deficiency with neurological symptoms 12:

• Hydroxocobalamin 1 mg IM on alternate days until no further improvement
• Then 1 mg IM every 2 months for life
• Urgent neurology consultation

For B12 deficiency without neurological symptoms 12:

• Hydroxocobalamin 1 mg IM three times weekly for 2 weeks
• Then 1 mg IM every 2-3 months for life

For folate deficiency (after excluding B12 deficiency) 12:

• Oral folic acid 5 mg daily for minimum 4 months

Management Based on Etiology

If MDS Confirmed

Management depends on IPSS-R risk score 3:

• Lower-risk MDS with anemia: Erythropoiesis-stimulating agents if EPO ≤500 mU/mL; lenalidomide if del(5q)
• Higher-risk MDS: Hypomethylating agents (azacitidine, decitabine) 3
• Eligible patients: Consider allogeneic stem cell transplantation (only curative option) 4, 2

If Essential Thrombocythemia/MPN Confirmed

• Calculate revised International Prognostic Score for thrombosis risk 6
• Low-dose aspirin for cardiovascular protection
• Hydroxyurea as first-line cytoreductive therapy if high thrombosis risk 6
• Address cardiovascular risk factors

If Secondary Thrombocytosis with B12/Folate Deficiency

• Treat vitamin deficiency as above
• Thrombocytosis should resolve with correction of underlying cause 8
• Monitor platelet count; persistent elevation after 3 months warrants MPN workup

Critical Pitfalls to Avoid

1. Do not assume reactive thrombocytosis without excluding MDS - MDS is a life-threatening diagnosis that requires specific treatment 2, 3

2. Do not treat with folate before checking B12 - can cause irreversible neurological damage 12, 13

3. Do not rely on ferritin alone in inflammatory states - ferritin <30 μg/L indicates iron deficiency without inflammation, but up to 100 μg/L may still represent iron deficiency with concurrent inflammation 11

4. Do not delay bone marrow biopsy in older adults - MDS incidence increases dramatically with age and early diagnosis impacts treatment options 2

5. Do not miss medication-induced macrocytosis - hydroxyurea, azathioprine, and other chemotherapy agents cause macrocytosis 1, 11